Product Source: N-terminal 6His-tagged recombinant human Abl, residues 27-end containing the M351T mutation. Expressed by baculovirus in Sf21 insect cells.

The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the M351T mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).

Protein Target: Abl

Target Sub-Family: TK

Also available in 250μg size as catalog # 14-757M - Call for pricing and availability.

Ni²⁺/NTA-agarose

50mM Tris/HCl pH7.5, 150mM NaCl, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution.

Store -70°C. For maximum recovery of product, centrifuge original vial prior to removing the cap.
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

Routinely evaluated by phosphorylation of Abltide.

For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.